Literature DB >> 33573335

Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy.

Gisella Figlioli1, Arcangela De Nicolo2, Irene Catucci1, Siranoush Manoukian3, Bernard Peissel3, Jacopo Azzollini3, Benedetta Beltrami3, Bernardo Bonanni4, Mariarosaria Calvello4, Davide Bondavalli4, Barbara Pasini5,6, Francesca Vignolo Lutati6, Paola Ogliara6, Monica Zuradelli7, Valeria Pensotti8, Giovanna De Vecchi8, Sara Volorio8, Paolo Verderio9, Sara Pizzamiglio9, Giuseppe Matullo5,6, Serena Aneli5, Giovanni Birolo5, Federica Zanardi10, Carlo Tondini11, Alberto Zambelli11, Luca Livraghi11,12, Michela Franchi11, Paolo Radice13, Paolo Peterlongo1.   

Abstract

Germline pathogenic variants (PVs) in the BRCA1 or BRCA2 genes cause high breast cancer risk. Recurrent or founder PVs have been described worldwide including some in the Bergamo province in Northern Italy. The aim of this study was to compare the BRCA1/2 PV spectra of the Bergamo and of the general Italian populations. We retrospectively identified at five Italian centers 1019 BRCA1/2 PVs carrier individuals affected with breast cancer and representative of the heterogeneous national population. Each individual was assigned to the Bergamo or non-Bergamo cohort based on self-reported birthplace. Our data indicate that the Bergamo BRCA1/2 PV spectrum shows less heterogeneity with fewer different variants and an average higher frequency compared to that of the rest of Italy. Consistently, four PVs explained about 60% of all carriers. The majority of the Bergamo PVs originated locally with only two PVs clearly imported. The Bergamo BRCA1/2 PV spectrum appears to be private. Hence, the Bergamo population would be ideal to study the disease risk associated with local PVs in breast cancer and other disease-causing genes. Finally, our data suggest that the Bergamo population is a genetic isolate and further analyses are warranted to prove this notion.

Entities:  

Keywords:  BRCA1; BRCA2; Bergamo province; Italy; breast cancer; pathogenic variants; spectrum

Year:  2021        PMID: 33573335     DOI: 10.3390/cancers13030532

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

Review 1.  Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.

Authors:  Filomena Ficarazzi; Manuela Vecchi; Maurizio Ferrari; Marco A Pierotti
Journal:  Breast       Date:  2021-05-12       Impact factor: 4.380

2.  Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

Authors:  Oubaida ElBiad; Abdelilah Laraqui; Fatima El Boukhrissi; Chaimaa Mounjid; Maryame Lamsisi; Tahar Bajjou; Hicham Elannaz; Amine Idriss Lahlou; Jaouad Kouach; Khadija Benchekroune; Mohammed Oukabli; Hafsa Chahdi; Moulay Mustapha Ennaji; Rachid Tanz; Yassir Sbitti; Mohammed Ichou; Khalid Ennibi; Bouabid Badaoui; Yassine Sekhsokh
Journal:  BMC Cancer       Date:  2022-02-25       Impact factor: 4.430

3.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

4.  Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers.

Authors:  Antonella Turchiano; Daria Carmela Loconte; Rosalba De Nola; Francesca Arezzo; Giulia Chiarello; Antonino Pantaleo; Matteo Iacoviello; Rosanna Bagnulo; Annunziata De Luisi; Sonia Perrelli; Stefania Martino; Carlotta Ranieri; Antonella Garganese; Alessandro Stella; Cinzia Forleo; Vera Loizzi; Marco Marinaccio; Ettore Cicinelli; Gennaro Cormio; Nicoletta Resta
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.